Daptomycin
Brand Names: Dapzura Rt
Methodology & AI Transparency ⓘ
Daptomycin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis.
- 2 Real-world patient consensus: Tracked across 10 patient dosage logs with a 91% satisfaction benchmark (RxCUI 403920).
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($13.4180/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Daptomycin): headache (10.2%), dizziness (9.5%), diarrhea (8.9%).
Ask our AI Specialists anything about Daptomycin
Daptomycin Mechanism, CYP450 Pathways & DailyMed Monograph
Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis. ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of use: Daptomycin for injection is not indicated for the treatment of pneumonia.
12.1 Mechanism of Action Daptomycin is an antibacterial drug . In clinical regimens (500 mg/20mL Injection, Powder, Lyophilized, for Suspension, 350 mg/7mL Injection, Powder, Lyophilized, for Solution), Daptomycin executes lipopeptide antibacterial target modulation documented under federal RxCUI 403920 and DailyMed 2023-11-14 labeling.
Clinical clearance of Daptomycin (Lipopeptide Antibacterial) relies on hepatic enzymatic processing and renal clearance proportional to creatinine clearance (daptomycin) with a Biphasic clearance with 11–15 hr terminal t½ under Daptomycin maintenance half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Daptomycin (500 mg/20mL Injection, Powder, Lyophilized, for Suspension) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after daptomycin administration.
FDA clinical labeling for Daptomycin restricts administration in daptomycin for injection is contraindicated in patients with known hypersensitivity to daptomycin .; known hypersensitivity to daptomycin ( 4 ) across 500 mg/20mL Injection, Powder, Lyophilized, for Suspension, 350 mg/7mL Injection, Powder, Lyophilized, for Solution, 500 mg/10mL Injection, Powder, Lyophilized, for Solution, 500 mg/1 Injection, Powder, Lyophilized, for Solution, 50 mg/mL Injection, Powder, Lyophilized, for Solution, with self-reported patient tracking dominated by headache (10.2% of reports), dizziness (9.5% of reports), diarrhea (8.9% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Daptomycin (lipopeptide antibacterial).
Botanical enzyme modulators may alter oral first-pass exposure of Daptomycin; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Daptomycin for injection is contraindicated in patients with known hypersensitivity to daptomycin .
- Known hypersensitivity to daptomycin ( 4 )
Logged Side-Effect Incidence (10 Reports)
Daptomycin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Daptomycin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Association Between Statin Use and Daptomycin-related Musculoskeletal side The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2022-10-12 • Meta-Analysis | Multi-cohort | 86/100 | PMID 35262686 ↗ |
Daptomycin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $13.4180/unit (~$402.54/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Daptomycin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Daptomycin RxNorm Concept ID | 403920 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $13.4180 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Daptomycin Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Daptomycin: FDA labeling (2023-11-14, NDC 14335-120), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Daptomycin community threads and patient logs by age, biological sex, dosage, and treatment duration.